Journal
BREAST
Volume 23, Issue 2, Pages 188-192Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2013.12.005
Keywords
Breast cancer; Neoadjuvant therapy; HER2; Hormone receptor; Targeted therapy; Trastuzumab
Categories
Ask authors/readers for more resources
Pathologic complete response (pCR) was noted to be prognostic in all but hormone receptor-positive (HR) breast cancer cases even when HER2 is overexpressed. Evocative data suggest that HER2-positive breast cancer patients are a heterogeneous population and a subset of HER2-positive and HR-positive tumors biologically behave more like HER2-negative. Identification and targeted monitoring of these patients is crucial to consolidate data aiming to optimize combination treatment with new agents, thereby avoiding overtreatment with chemotherapy. The questions surrounding HER2-positive and HR-positive breast cancer patients treatment as well as the potential direction towards development of surrogate markers alternative to pCR are discussed. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available